COVID < back
SOFI (Intelligent Physical Observation System)
At MINO Labs we do COVID-19 PCR tests (SARS-CoV-2), we have sample collection services for Government Institutions, Hospitals, Corporations, Industries and Individuals (with and without home-delivery service).
Contact an agent for more information:
Our priority is people's health, so we have PCR (Polymeric Chain Reaction) diagnostic tests to detect COVID-19, which has a great advantage in the current situation, since it is can be done at home.
The microbiological diagnosis of SARS-CoV-2, an agent of COVID-19 (2019 new coronavirus disease) is important for both the management of the individual disease and the current pandemic.
NUCLEIC ACID DETECTION TESTS: POLYMERASE CHAIN REACTION (PCR)
The reverse transcriptase polymerase chain reaction test is a molecular technique for detecting and amplifying nucleic acids, that is, genetic material, RNA, of SARS-CoV-2 in different clinical biological samples.
It is currently the reference and choice technique for the diagnosis of COVID-19.
+ more information
SOFI applied to the COVID-19 has a patented algorithm that uses a PPG technology engine, which can read heart rate, respiratory rate and oxygenation in the blood, as well as approximate the temperature using only the camera and the cell phone flash.
In addition to having smart questionnaires, location monitoring to detect risk factors, contact with other infected users to channel them and perform rapid tests, all this while generating a type of passport in which the user has to measure their vital signs and comply with the risk algorithms to be able to attend work. Companies or institutions are assigned a control panel where they can monitor their users in real time to find out which ones require a quick COVID test, isolation and which ones can assist at work, issuing recommendations or warnings to the user as necessary.
How does it work?
1: Perform a quick test on all collaborators. Once the result is known, the application must be downloaded and the form filled out. SOFI will detect risk factors and segment the infected, healthy and possible risk factors.
2: Monitoring of vital signs (temperature, heart rate, respiratory rate and oxygenation in the blood), location tracking to the user to alert him of risk areas or detect if he has contact with any infected user.
3: Through the panel, companies / entities will be able to see in real time the people who have the passport to go to work and the same algorithm will show them the users who must remain in isolation and the users with the need to take the rapid test. one more time.
4: Users with their pass to go to work should assist with all the necessary security measures, which SOFI will be reminding you in real time such as: Wash the controls, use mouth covers, keep healthy distance, and many other tips to keep you healthy and not infect you, in addition to measuring your vital signs throughout the day.
The application of SOFI in its different directions has won national and international awards representing Mexico on different occasions, with a proposal to reactivate the economy, especially now with COVID-19.
• Easy to handle for doctors and professionals.
• No special conditions for the storage and transportation of equipment are required.
• Works with whole blood, serum and plasma.
• Tests for 2 IgM and IgG antibodies simultaneously.
• 93.43% + precision.
• Exponentially faster.
• Exponentially more profitable.
• Early detection and removal.
• Accessible to anyone.
• A viable precautionary measure.
USE AND INTERPRETATION OF RESULTS
the control line is the only line visible on the reagent marker. No IgG or IgM antibody was detected. These results do not exclude infection. If symptoms persist, a new sample should be taken from the patient within 3-5 days and the test repeated.
Positive IgM and IgG:
Control line C, IgM line, and IgG line are clearly visible in the reagent marker. The IgM and IgG antibodies have tested positive, indicating that the patient is in the late acute phase of infection.
Control line C and IgG line are visible on the reagent marker. The results show that the IgG antibody was positive. This indicates that the patient is in the recovery stage of the infection.
Control line C and IgM line are visible in the reagent marker. The Ig M antibody was positive, indicating that the patient is in the acute stage of infection.
Invalid test results:
if the control line does not appear in the reagent marker, the test result is invalid regardless of whether other lines are visible in the test bar. Retest with a new test.
It is widely accepted that IgM provides the first line of defense during viral infections, followed by the generation of adaptive high-IgG responses for long-term immunity and immune memory. Therefore, the COVID-19 IgM and IgG antibody test is an effective method for rapid diagnosis of COVID-19 infection.
Furthermore, detection of COVID-19 IgM antibodies tends to indicate recent exposure to COVID-19, while detection of COVID-19 IgG antibodies indicates a later stage of infection. Therefore, this combined antibody test could also provide information on the stage of infection.
During the test, the sample reacts with the particles coated with the COVID-19 antigen in the cassette test.
The mixture migrates chromatographically throughout the plate and reacts with immobilized anti-human IgG in the linear IgG region of the test. If the sample contains IgG antibodies to COVID-19, a colored line will appear in the linear IgG region of the test.
Likewise, anti-human IgM is immobilized in the linear IgM region of the test. If the sample contains IgM antibodies to COVID-19, the conjugated sample complex reacts with anti-human IgM and a colored line will appear in the linear IgM region of the test.
If the sample does not contain antibodies to COVID-19, no colored line will appear in any of the linear regions of the test, indicating a negative result. In order to serve as a procedure control, a colored line will always appear in the region of the test control line, indicating that an adequate volume of sample has been added and a wick effect has been produced on the membrane.
Clinical study report Rapid Cassete Test IgG / IgM 2019-nCoV (whole blood / plasma / serum) with positive samples 2019-nCoV and negative confirmed by PCR method (Ref .: BNCP-402 / BNCP-402S).
A statistical comparison was made between the results that yielded a sensitivity of 87.01%, a specificity of 98.89% and an accuracy of 93.43%. Regarding the IgG test, we have counted the positive rate of the 77 patients during the convalescence period.
People with COVID-19 have reported a wide range of symptoms, from mild symptoms to severe illness.
Symptoms may appear 2-14 days after exposure to the virus. People with these symptoms may have COVID-19:
• Fever or chills
• Shortness of breath or trouble breathing
• Muscle or body aches
• New loss of taste or odor
• Sore throat
• Stuffy or runny nose
• Nausea or vomiting
This list does not include all possible symptoms. CDC will continue to update this list as we learn more about COVID-19.
We have sample collection services for Government Institutions, Hospitals, Corporations, Industries and Individuals (with and without home-delivery service).
For more information send an email to:
Monte Pelvoux 130 Piso 3
Lomas de Chapultepec
Miguel Hidalgo CP 11000 Mexico City